Compare Adaptive Biotechnologies Corp (ADPT) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Kinder Morgan Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Kinder Morgan Inc trades at $32.35 (market cap $72.28B). The key difference: Kinder Morgan Inc is far larger — about 21.7× Adaptive Biotechnologies Corp's market cap, and Kinder Morgan Inc pays a 3.62% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | KMI | |
|---|---|---|
Market Cap | $3.33B | $72.28B |
Sector | Health | Energy |
52-Week High | $22.37 | $34.31 |
52-Week Low | $10.24 | $25.84 |
Enterprise Value | $3.19B | $104.16B |
Dividend Yield | — | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
KMI trades at $32.49, up 1.34% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.48, and maintains a solid dividend of $0.30 per share. Revenue grew to $16.94B in 2025, with net income reaching $3.06B, reflecting an 18.04% margin. Analyst consensus is mixed, with 47% buy ratings and 50% hold.
KMI's outlook is supported by stable cash flows from fee-based contracts and a $10.1B project backlog focused on natural gas infrastructure. Key risks include high debt levels and exposure to energy market volatility. The stock offers income potential with a near 4% yield, but investors should monitor execution on growth projects and commodity price trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
